stockmarketproxy
/
VTRSNasdaq SEC EDGAR

Viatris Inc

Pharmaceutical Preparations·CANONSBURG, PA·FY end 12/31·CIK 1792044
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$14.3B$14.7B$15.4B$16.3B$17.9B
Gross Profit$5.0B$5.6B$6.4B$6.5B$5.6B
Operating Income-$2.7B$10.1M$766.2M$1.6B-$34.0M
Net Income——————
Operating CF$2.3B$2.3B$2.8B$3.0B$3.0B
Capex$378.8M$326.0M$377.0M$406.0M$457.2M
Free Cash Flow$1.9B$2.0B$2.4B$2.5B$2.6B
Buybacks$500.5M$250.0M$250.0M——
Dividends——————
Gross Margin35.1%38.2%41.7%40.0%31.2%
Operating Margin-18.6%0.1%5.0%9.9%-0.2%
Net Margin——————
FCF Margin13.5%13.4%15.7%15.7%14.3%
R&D / Revenue————4.2%—
Effective Tax4.1%-1.8%73.0%26.1%-91.0%
Debt / Equity——————
Buybacks / FCF25.8%12.6%10.3%——

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
VTRS
327:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
VTRS
$15M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
VTRS
—
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%